|
Table 1: Characteristics of
included studies |
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year |
Author |
Country |
Level |
In/Com? |
Inclusion criteria |
n |
S |
C |
Mean age |
Random? |
Alloc conc? |
Blinding? |
|
1978 |
Golden |
|
1b |
In-Px |
Wellcome |
10 |
10 |
10 |
15.3 ± 7.0 |
Yes |
Yes |
Double-blind |
|
|
|
|
|
|
|
|
|
|
|
|
|
Placebo |
|
1981 |
Golden |
|
2b |
In-Px |
Wellcome |
34 |
24 |
10 |
12.5 ±0.9m |
No |
No |
No |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1988 |
Khanum |
|
2b |
In-Px |
Waterlow: Severe |
60 |
30 |
30 |
29 m |
No: Alternate |
No |
No |
|
|
|
|
|
|
|
|
|
|
|
allocation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1988 |
Simmer |
|
2b |
In-Px |
McLaren scoring |
25 |
12 |
11 |
38.9 ± 4.6m |
No: Alternate |
No |
No |
|
|
|
|
|
|
WFH<70% |
|
|
|
|
allocation |
|
|
|
1988 |
Gatheru |
|
2b |
In-Px |
Wellcome |
82 |
31 |
27 |
1-3 y |
No: Alternate |
No |
No |
|
|
|
|
|
|
All had: Kwashiorkor |
|
|
|
|
allocation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||